Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6578-6588

  Ban, Jozef ^a   Aryee, Dave N T ^a,b   Fourtouna, Argyro ^a   Van Der Ent, Wietske ^c   Kauer, Max ^a   Niedan, Stephan ^a   Machado, Isidro ^d   Rodriguez Galindo, Carlos ^e   Tirado, Oscar M ^f   Schwentner, Raphaela ^a   Picci, Piero ^g   Flanagan, Adrienne M ^h   Berg, Verena ^a   Strauss, Sandra J ^h   Scotlandi, Katia ^g   Lawlor, Elizabeth R ⁱ   Snaar Jagalska, Ewa ^c   Llombart Bosch, Antonio ^d   Kovar, Heinrich ^a,b  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LEIDEN UNIVERSITY   (Netherlands)

^d Department of Pathology University Medical School ^*  (Spain)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^g RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROLASE INHIBITOR; NOTCH RECEPTOR; PROTEIN P53; SIRTUIN 1; TENOVIN 6; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; EWS-FLI FUSION PROTEIN; HAIRY, HRT1 PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN; RNA BINDING PROTEIN EWS; SIRT1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR FLI 1;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DEACETYLATION; DRUG EFFICACY; EWING SARCOMA; EWS FLI1 GENE; GENE SILENCING; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; METASTASIS; MODULATION; NONHUMAN; ONCOGENE; PROTEIN DEPHOSPHORYLATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SARCOMA, EWING; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; NEOPLASM METASTASIS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RECEPTORS, NOTCH; REPRESSOR PROTEINS; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SIGNAL TRANSDUCTION; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH;

EID: 84918558904     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1736     Document Type: Article

References (50)

1. Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K, et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 2011;473:234-8.
2. Dotto GP. Notch tumor suppressor function. Oncogene 2008;27:5115-23.
3. Ban J, Bennani-Baiti I, Kauer M, Schaefer KL, Poremba C, Jug G, et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 2008;68:7100-9.
4. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, et al. A molecular function map of Ewing's sarcoma. PLoS One 2009;4:e5415.
5. Bennani-Baiti I, Aryee D, Ban J, Machado I, Kauer M, Mühlbacher K, et al. Notch signaling is off and is uncoupled from HES1 expression in Ewing's sarcoma. J Pathol 2011;225:353-63.
6. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606.
7. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107:137-48.
8. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012;13:225-38.
9. Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, et al. A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol Cell 2011;42:689-99.
10. Fang Y, Nicholl MB. Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett 2011;306:10-4.
11. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59.
12. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008;133:612-26.
13. Machado I, Lopez Guerrero JA, Navarro S, Mayordomo E, Scotlandi K, Picci P, et al. Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. Virchows Arch 2013;462:665-71.
14. Lai R, Navid F, Rodriguez-Galindo C, Liu T, Fuller CE, Ganti R, et al. STAT3 is activated in a subset of the Ewing sarcoma family of tumours. J Pathol 2006;208:624-32.
15. Ghotra VP, He S, De Bont H, Van Der Ent W, Spaink HP, Van De Water B, et al. Automated whole animal bio-imaging assay for human cancer dissemination. PLoS One 2012;7:e31281.
16. Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011;2:456-62.
17. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-22.
18. Lim YP, Lim TT, Chan YL, Song AC, Yeo BH, Vojtesek B, et al. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 2007;26:1517-21.
19. Park JH, Smith RJ, Shieh SY, Roeder RG. The GAS41-PP2Cbeta complex dephosphorylates p53 at serine 366 and regulates its stability. J Biol Chem 2011;286:10911-7.
20. Lu Z, Wan G, Guo H, Zhang X, Lu X. Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx. Cell Signal 2013;25:796-804.
21. Haneda M, Kojima E, Nishikimi A, Hasegawa T, Nakashima I, Isobe K. Protein phosphatase 1, but not protein phosphatase 2A, dephosphorylates DNA-damaging stress-induced phospho-serine 15 of p53. FEBS Lett 2004;567:171-4.
22. Mi J, Bolesta E, Brautigan DL, Larner JM. PP2A regulates ionizing radiation-induced apoptosis through Ser46 phosphorylation of p53. Mol Cancer Ther 2009;8:135-40.
23. Li HH, Cai X, Shouse GP, Piluso LG, Liu X. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J 2007;26:402-11.
24. Dohoney KM, Guillerm C, Whiteford C, Elbi C, Lambert PF, Hager GL, et al. Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage. Oncogene 2004;23:49-57.
25. Serrano MA, Li Z, Dangeti M, Musich PR, Patrick S, Roginskaya M, et al. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 2013;32:2452-62.
26. Heisig J, Weber D, Englberger E, Winkler A, Kneitz S, Sung WK, et al. Target gene analysis by microarrays and chromatin immunoprecipitation identifies HEY proteins as highly redundant bHLH repressors. PLoS Genet 2012;8:e1002728.
27. Fischer A, Leimeister C, Winkler C, Schumacher N, Klamt B, Elmasri H, et al. Hey bHLH factors in cardiovascular development. Cold Spring Harb Symp Quant Biol 2002;67:63-70.
28. Consortium EP. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011;9:e1001046.
29. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008;13:454-63.
30. Van Der Ent W, Jochemsen AG, Teunisse AF, Krens SG, Szuhai K, Spaink HP, et al. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. J Pathol 2014;233:415-24.
31. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysinespecific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol 2012;43:1300-7.
32. Xie M, Liu M, He CS. SIRT1 regulates endothelial Notch signaling in lung cancer. PLoS One 2012;7:e45331.
33. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 2004;306:2105-8.
34. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci US A 2008;105:13421-6.
35. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, et al. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 2012;226:796-805.
36. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, et al. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009;28:445-60.
37. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer Kuntschik M, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993;8:2683-90.
38. MacCallum SF, Groves MJ, James J, Murray K, Appleyard V, Prescott AR, et al. Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep 2013;3:1275.
39. Chen R, Dioum EM, Hogg RT, Gerard RD, Garcia JA. Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner. J Biol Chem 2011;286:13869-78.
40. Yamakuchi M. MicroRNA regulation of SIRT1. Front Physiol 2012;3:68.
41. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005;123:437-48.
42. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, et al. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 2010;6:599-612.
43. Ford J, Ahmed S, Allison S, Jiang M, Milner J. JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 2008;7:3091-7.
44. Guo X, Williams JG, Schug TT, Li X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem 2010;285:13223-32.
45. Jang SY, Kim SY, Bae YS. p53 deacetylation by SIRT1 decreases during protein kinase CKII downregulation-mediated cellular senescence. FEBS Lett 2011;585:3360-6.
46. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, et al. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res 2012;72:4394-404.
47. Wen L, Chen Z, Zhang F, Cui X, Sun W, Geary GG, et al. Ca2+/calmodulin-dependent protein kinase kinase beta phosphorylation of Sirtuin 1 in endothelium is atheroprotective. Proc Natl Acad Sci US A 2013;110:E2420-7.
48. Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol 2007;9:1253-62.
49. Bilke S, Schwentner R, Yang F, Kauer MO, Jug G, Walker RL, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res 2013;23:1797-809.
50. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, et al. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 2011;30:2173-80.